As shown in Figure 3, vaccination of H5N1-M2e with either FA or SAS, could protect 80% (8/10) of mice from lethal challenge of H7N9 virus.
These peptides protected mice from lethal MRSA challenges, despite having their antibacterial activity diminished in physiological high salt conditions.
Passive transfer of immune sera to the VP proteins did not protect unvaccinated mice from lethal disease.
Moreover, the anti-HBc-V/1/2 sera protected neonatal mice from lethal challenge of EV71 and CVA16.
In the present study, we showed that Z3G1 significantly protected mice from lethal infection when treatment was initiated 3 days post infection.
Vaccination resulted in peptide-specific immune responses, augmented HA-specific antibody responses and protection of HLA-DR4 transgenic mice from lethal PR8 influenza virus challenge.
The monovalent vaccine with RG-epitope-chimeric H5N1 protected mice from lethal challenge with H5N1s of different clades, including clade 1.0, 2.2, 2.2 and 2.3.
The vaccine completely protected mice from lethal doses of anthrax toxin, according to results published online this week in the Proceedings of the National Academy of Sciences.
Nasal application of human IL-6 and tetanus toxin (TT) enhanced serum TT specific antibodies and Th2 response, protecting mice from lethal challenge with tetanus toxin (Boyaka et al., 1999).
A cocktail of nanospheres with diverse degradation kinetics showed persistent therapeutic effects in acute hepatitis, and only nanospheres that targeted hepatocytes and controlled degradation rescued mice from lethal hepatic injury.
Protection of mice from lethal intranasal VACV challenge required intranasal immunization with PIV5-L1R/B5R in a prime-boost protocol, and correlated with low VACV-induced pathology in the respiratory tract and anti-VACV neutralizing antibody.
